Farallon Capital Management sold its entire position in Vaxcyte Inc. (PCVX), a clinical-stage vaccine company, during the second quarter of 2026. The major investment firm divested all 1.26 million of its shares, a stake previously valued at $73.28 million. This move eliminated what was a 0.42% position within Farallon's disclosed portfolio.
The transaction was revealed in a quarterly 13F filing with the SEC on August 14, 2026, which details the firm's holdings as of June 30, 2026. Because these filings are delayed, the sale could have happened at any point during the April-to-June period and does not necessarily reflect the firm's current portfolio.